What is VKTX's five-year median P/E?

There are not enough weekly readings yet for a five-year median P/E.

Does a low historical rank mean a stock is a buy?

No. The rank compares VKTX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Viking Therapeutics Inc (VKTX) P/E ratio history

Health Care

$25.36

Latest weekly close · Market cap $3.0B

Viking Therapeutics has no P/E right now because its earnings over the last twelve months are negative (as of Oct 29, 2026).

No P/S: recent financial data is missing.
No EV/Sales: recent financial data is missing.
No EV/EBITDA: recent financial data is missing.

No P/E chart for VKTX right now

VKTX has no weekly P/E history to chart yet.

P/E

n/mnot ranked

P/E needs positive earnings to be ranked.

Growth, last 12 months vs the year before

Revenue: n/m
EPS: n/m

Health Care peers on P/E

Each percentile compares a stock with its own last five years.

Compare VKTX with peers

Health Care peers of VKTX on P/E
Stock	P/E	Versus its own history	5-year percentile
ABBVAbbVie	80.8×	Above its usual range	76
AMGNAmgen	28.1×	Above its usual range	80
ARWRArrowhead Pharmaceuticals Inc	n/m	Not ranked	n/m, not ranked
BBIOBridgebio Pharma Inc	n/m	Not ranked	n/m, not ranked
BIIBBiogen	105.2×	Historically high	100

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on VKTX

No articles about VKTX yet. How valuation percentiles work

Loading peers and related research…

About this history

What is VKTX's current P/E?: Viking Therapeutics has no P/E right now because its earnings over the last twelve months are negative (as of Oct 29, 2026).
What is VKTX's five-year median P/E?: There are not enough weekly readings yet for a five-year median P/E.
Does a low historical rank mean a stock is a buy?: No. The rank compares VKTX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.